# PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

> **NCT07209059** · PHASE2 · RECRUITING · sponsor: **National Research Center for Hematology, Russia** · enrollment: 30 (estimated)

## Conditions studied

- Hodgkin Lymphoma
- Hodgkin Disease
- Advanced Hodgkin Lymphoma

## Interventions

- **DRUG:** Nivolumab
- **OTHER:** N-EACOPD-14
- **OTHER:** N-AVD

## Key facts

- **NCT ID:** NCT07209059
- **Lead sponsor:** National Research Center for Hematology, Russia
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-29
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07209059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07209059, "PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07209059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*